INDICATIONS
X

  • ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.

  • ENBREL is indicated for chronic moderate to severe plaque psoriasis (PsO) in children 4 years and older and adults who may benefit from taking injections or pills (systemic therapy) or phototherapy (ultraviolet light).

  • ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used with or without methotrexate.

  • ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

  • ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.

to close ⌄
CHANGE CONDITION
  • moderate to severe

    Rheumatoid Arthritis

  • moderate to severe

    Plaque Psoriasis

  • Psoriatic Arthritis

  • Ankylosing Spondylitis

  • moderate to severe polyarticular

    Juvenile Idiopathic Arthritis (JIA)

  • moderate to severe

    Rheumatoid Arthritis

  • moderate to severe

    Plaque Psoriasis

  • Psoriatic Arthritis

  • Ankylosing Spondylitis

  • moderate to severe polyarticular

    Juvenile Idiopathic Arthritis (JIA)

    EDIT

    Paying for Enbrel®

    The list price for ENBREL is $1,293.52*† per weekly 50 mg dose.

    Note: The recommended dosing for adults with moderate to severe RA, PsA, AS is 50 mg weekly.

    For patients with moderate to severe plaque psoriasis, the recommended dose is 50 mg twice weekly for the first 3 months followed by 50 mg weekly thereafter.

    For pediatric patients with moderate to severe JIA or for moderate to severe plaque psoriasis, the recommended dose is 50 mg weekly for patients weighing 63 kg (138 lb) or more. For patients weighing less than 63 kg (138 lb), the recommended dose is 0.8 mg per kg weekly (with a maximum of 50 mg per week).

    Most patients do not pay the list price. Your actual cost will vary. Talk to your insurance provider.

    The information below will help you find the insurance plan most like yours.

     

    *List price is also referred to as wholesale acquisition cost or WAC. WAC is the price at which Amgen sells its products to wholesalers. ENBREL is administered as a self-injection as prescribed by a healthcare professional.

    †Source: AnalySource. Accessed on January 17, 2019.

    Your out-of-pocket cost may vary and what you pay for ENBREL will depend on your insurance plan. Each plan has different out-of-pocket costs, and most plans include an annual deductible.

    Your out-of-pocket costs may vary depending on whether or not you have met your deductible.

    For questions regarding cost, please call ENBREL Support® at 1-888-4ENBREL (1-888-436-2735).


    Key terms

    It's not always easy to keep up with what everything means when discussing prescription costs. So here are the definitions of some commonly-used terms related to prescription cost to help clear things up.

    COMMERCIAL OR PRIVATE INSURANCE: Health insurance that's available through work or a healthcare exchange.

    CO-PAY AND CO-INSURANCE: Payments you make each time you get a medical service after reaching your deductible. A co-pay, which is also called co-payment, is typically a fixed amount you pay for your prescription (example: $20). Co-insurance is a percentage of your prescription cost (example: 10%).

    DEDUCTIBLE: How much you have to spend for covered health services before your insurance company pays anything (except free preventive services).

    OUT-OF-POCKET: The amount that you are responsible for paying after insurance has paid their portion of the cost of a covered health service.

    OUT-OF-POCKET MAXIMUM: The most you have to spend for covered services in a year. After you reach this amount, your insurance may pay 100% of covered services.

    Do you have Commercial Insurance?

    76% of prescriptions, including those where the Enbrel® Co-Pay Card1 was used, cost $50 or less per month.2,3 The remaining 24% of prescriptions cost an average of $469 per month.4,5

    1Eligibility criteria and limits apply. For more information about this program, call 1-888-4ENBREL or visit www.enbrel.com.
    2These data are based on ENBREL co-pay card paid claims data and paid claims data from national data providers for the period 1/1/2018–12/31/2018.
    3A 1-month supply of ENBREL is typically 4 weekly 50 mg doses.
    4These data are based on paid claims data from national data providers for the period 1/1/2018–12/31/2018.
    5Your actual cost may vary depending on your dose, insurance coverage, and eligibility for support programs. Talk to your insurance provider for specific information about your prescription coverage.

    The Enbrel® Co-Pay Card may help lower your ENBREL monthly out-of-pocket costs

    Key terms related to your Enbrel® Co-Pay Card

    It's not always easy to keep up with what everything means when discussing prescription costs. So here are the definitions of some commonly-used terms related to prescription cost to help clear things up.

    COMMERCIAL OR PRIVATE INSURANCE: Health insurance that's available through work or a healthcare exchange.

    CO-PAY AND CO-INSURANCE: Payments you make each time you get a medical service after reaching your deductible. A co-pay, which is also called co-payment, is typically a fixed amount you pay for your prescription (example: $20). Co-insurance is a percentage of your prescription cost (example: 10%).

    DEDUCTIBLE: How much you have to spend for covered health services before your insurance company pays anything (except free preventive services).

    OUT-OF-POCKET: The amount that you are responsible for paying after insurance has paid their portion of the cost of a covered health service.

    OUT-OF-POCKET MAXIMUM: The most you have to spend for covered services in a year. After you reach this amount, your insurance may pay 100% of covered services.


    Eligibility requirements apply.

    ENBREL Co-Pay Terms & Conditions

    SUMMARY OF TERMS AND CONDITIONS

    It is important that every patient read and understand the full Enbrel® Co-Pay Card Terms and Conditions. The following summary is not a substitute for reviewing the Terms and Conditions in their entirety.

    As further described below, in general,

    • The Enbrel® Co-Pay Card is open to patients with commercial insurance, regardless of financial need. The program is not valid for patients whose ENBREL prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs. It is not valid for cash paying patients or where prohibited by law. (See ELIGIBILITY section below.)
    • The Enbrel® Co-Pay Card may help lower your ENBREL monthly out-of-pocket costs. Monthly out-of-pocket costs include co-payment, co-insurance, and deductible out-of-pocket costs. The Enbrel® Co-Pay Card provides support up to the Maximum Program Benefit or Patient Total Program Benefit. If a patient’s commercial insurance plan imposes different or additional requirements on patients who receive Enbrel® Co-Pay Card benefits, Amgen has the right to reduce or eliminate those benefits. Whether you are eligible to receive the Maximum Program Benefit or Patient Total Program Benefit is determined by the type of plan coverage you have. Please ask your ENBREL Support® Representative to help you understand eligibility for the Enbrel® Co-Pay Card, whether your particular insurance coverage is likely to result in your reaching the Maximum Program Benefit or your Patient Total Program Benefit amount by calling 1-888-436-2735 and selecting option 1. (See PROGRAM BENEFITS section below.)

    Our Program changes on January 1, 2020:

    • Beginning January 1, 2020, all Enbrel® patients, new and ongoing, pay $5 out-of-pocket at every refill and Amgen will pay the remaining eligible out-of-pocket costs on behalf of the patient until the Amgen payments have reached either the Maximum Program Benefit or the Patient Total Program Benefit. Patients are responsible for all amounts that exceed this limit. (See PROGRAM DETAILS section below.)

    Until December 31, 2019,

    • New to Enbrel® patients receive up to the first 6 months (or until December 31, 2019, whichever is sooner) of their new Enbrel® prescription with no out-of-pocket cost, and Amgen will pay the remaining eligible out-of-pocket costs on behalf of the patient until the Amgen payments have reached either the Maximum Program Benefit or the Patient Total Program Benefit.
    • Until December 31, 2019, new Enbrel® patients who have completed their initial 6-month program participation and ongoing Enbrel® patients pay $10 out-of-pocket at every refill, while Amgen will pay the remaining eligible out-of-pocket Enbrel® prescription costs on behalf of the patient until the Amgen payments have reached either the Maximum Program Benefit or the Patient Total Program Benefit.
    • On December 31, 2019, the first 6-month offer for new Enbrel® prescription with no out-of-pocket cost ends, including for patients who have been enrolled in this offer for less than 6 months.

    (See PROGRAM DETAILS section below.)

    I. ELIGIBILITY

    *Eligibility Criteria: Subject to program limitations and terms and conditions, the Enbrel® Co-Pay Card is open to patients who have an ENBREL prescription and who have commercial or private insurance, including plans available through state and federal healthcare exchanges. This program helps eligible patients cover out-of-pocket costs related to ENBREL, up to program limits. There is no income requirement to participate in this program.

    This offer is not valid for patients whose Enbrel® prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs. It is not valid for cash-paying patients or where prohibited by law. A patient is considered cash-paying where the patient has no insurance coverage for Enbrel® or where the patient has commercial or private insurance but Amgen in its sole discretion determines the patient is effectively uninsured because such coverage does not provide a material level of financial assistance for the cost of an Enbrel® prescription.

    II. PROGRAM BENEFITS

    The Enbrel® Co-Pay Card does not cover out-of-pocket costs for any patient whose selected coverage option under their commercial insurance plan does not apply Enbrel® Co-Pay Card payments to satisfy the patient’s co-payment, deductible, or co-insurance for ENBREL. Patients with these plan limitations are not eligible for the Enbrel® Co-Pay Card but may be eligible for other needs-based assistance provided by Amgen. These programs are often referred to as accumulator adjustment programs. If you believe your commercial insurance plan may have such limitations, please contact ENBREL Support® at 1-888-436-2735. The Enbrel® Co-Pay Card also may provide a reduced benefit amount, unilaterally determined by Amgen in its sole discretion, to satisfy the out-of-pocket cost sharing requirement for any patient whose plan or plan agent (including, but not limited to, a Pharmacy Benefit Manager) requires enrollment in the Enbrel® Co-Pay Card as a condition of the plan or PBM waiving some or all of an otherwise applicable patient out-of-pocket cost sharing amount. These programs are often referred to as copay maximizer programs. If you believe your commercial insurance plan may have such limitations, please contact ENBREL Support® at 1-888-436-2735. Health plans, Specialty pharmacies, Pharmacy Benefit Managers (“Plan Administrators”) are prohibited from enrolling patients in the Enbrel® Co-Pay program. Plan Administrators are prohibited from assisting patients with enrollment in the Enbrel® Co-Pay Card. The patient, or his/her legal representative, must personally enroll in the Enbrel® Co-Pay Card Program in order to be eligible for program benefits.

    If at any time a patient begins receiving prescription drug coverage under any state or government (including but not limited to Medicare, Medicaid, TRICARE, Department of Defense, or Veteran Affairs programs), the patient will no longer be able to use this card and you must contact ENBREL Support® at 1-888-436-2735. (8:00am-8:00pm eastern time, Monday-Friday) to stop your participation in this program.

    Patients may not seek reimbursement for the value received from the Enbrel® Co-Pay Card from any third-party payers, including a flexible spending account or healthcare savings account. Participating in this program means that you are ensuring you comply with any required disclosure regarding your participation in the Enbrel® Co-Pay Card of your insurance carrier or pharmacy benefit manager. Restrictions may apply. Offer subject to change or discontinuation without notice. This is not health insurance.

    III. PROGRAM DETAILS

    For all eligible patients the Enbrel® Co-Pay Card offers:

    • A program benefit that covers the patient’s eligible out-of-pocket prescription costs for ENBREL (co-pay, deductible, or co-insurance) on behalf of the patient, up to a Maximum Program Benefit determined by the program per calendar year.
    • New to Enbrel® patients receive up to the first 6 months (or until December 31, 2019, whichever is sooner) of their new Enbrel® prescription with no out-of-pocket cost, and Amgen will cover on behalf of the patient all eligible out-of-pocket prescription costs (up to their Patient Total Program Benefit, described below).
    • Until December 31, 2019, new Enbrel® patients who have completed their initial 6-month program participation and ongoing Enbrel® patients pay $10 out-of-pocket at every refill, and Amgen will pay on behalf of the patient, the remaining eligible out-of-pocket prescription costs (up to the Patient Total Program Benefit described below. Enbrel® patients are responsible for all amounts that exceed this limit).
    • On January 1, 2020, all Enbrel® patients, new and ongoing, pay $5 out-of-pocket at every refill (and Amgen will pay on behalf of the patient the remaining eligible out-of-pocket prescription costs up to the Patient Total Program Benefit described below. Enbrel® patients are responsible for all amounts that exceed this limit).

      • Maximum Program Benefit, Patient Total Program Benefit, Benefits May Change, End or Vary: The program provides up to a Maximum Program Benefit of assistance to reduce a patient’s out-of-pocket prescription costs that Amgen will provide per patient for each calendar year, which must be applied to the Enbrel® patient’s out-of-pocket costs (co-pay, deductible, or co-insurance). Patient Total Program Benefit amounts are unilaterally determined by Amgen in its sole discretion and will not exceed the Maximum Program Benefit. The Patient Total Program Benefit may be less than the Maximum Program Benefit, depending on the terms of a patient’s prescription drug plan, and may vary among individual patients covered by different plans, based on factors determined solely by Amgen, to ensure all programs funds are used for the benefit of the patient. Each patient is responsible for costs above the Patient Total Program Benefit amounts. Please ask your ENBREL Support® Representative to help you understand whether your particular insurance coverage is likely to result in your reaching the Maximum Program Benefit or your Patient Total Program Benefit amount by calling 1-888-436-2735 and selecting option 1. Participating patients are solely responsible for updating Amgen with changes to their prescription health insurance including, but not limited to, initiation of insurance provided by the government, the addition of any coverage terms that do not apply Enbrel® Co-Pay Card benefits to reduce a patient’s out-of-pocket costs, such as accumulator adjustment benefit design or a copay maximization program. Participating patients are responsible for providing Amgen with accurate information necessary to determine program eligibility. By accepting payments from Amgen made on behalf of participating patients, participating PBMs and Plans likewise are responsible for providing Amgen with accurate information regarding patient eligibility. Patients may use the card every time they fill their ENBREL prescription. Benefits reset each calendar year. Enrollment in the program is for 12 months. Patients may participate in the program for 12 months, or continue in the program after that, provided s/he continues to meet all of the program’s eligibility requirements during participation in the program, and with program enrollment renewal every 12 months. Patients can enroll/reenroll by calling 1-888-436-2735 and selecting option 1.

    Do you have Medicare?

    77% of prescriptions cost $50 or less per month1, and the remaining 23% of prescriptions cost an average of $415 per month. 2,3,4,5

    1A one-month supply of ENBREL is typically 4 weekly 50 mg doses.
    2These data are based on paid claims data from national data providers for the period 1/1/2018 – 12/31/2018.
    3Your out-of-pocket costs can vary throughout the year depending on which phase of the Part D benefit you are currently in. Medicare Part D drug coverage is divided into four phases, each with a different cost sharing amount. Those phases are 1) Deductible, 2) Initial coverage, 3) Coverage gap, 4) Catastrophic.
    4These amounts may vary if you are eligible for the Extra Help program. For more information, please visit Extra Help with Medicare Prescription Drug Plan Costs from the Social Security Administration (SSA) at https://www.ssa.gov/benefits/medicare/prescriptionhelp. Accessed on July 22, 2019.
    5Your actual cost may vary depending on your dose and insurance coverage. Talk to your insurance provider for specific information about your prescription coverage.

    Do you have Medicaid?

    93% of prescriptions cost $10 or less per month1, and the remaining 7% of prescriptions cost an average of $239 per month.2,3,4

    1A one-month supply of ENBREL is typically 4 weekly 50 mg doses. 2These data are based on paid claims data from national data providers for the period 1/1/2018 – 12/31/2018. 3To find out if you qualify for Medicaid, or for more information about copayments in your state, please visit: https://www.medicaid.gov/state-overviews/index.html. 4Your actual cost may vary depending on your dose and insurance coverage. Talk to your insurance provider for specific information about your prescription coverage.

    Our team of Insurance Solutions Specialists know about Medicare and Medicaid and can:

    • Help you figure out your out-of-pocket ENBREL prescription costs based on your specific Medicare Part D plan benefits
    • Help you find answers to any ENBREL questions you may have about your Medicare Part D or Medicaid plan
    • Refer you to organizations that may be able to help with out-of-pocket costs*
    • Help you understand whether you’re qualified for low-income subsidy (also known as LIS extra-help) and help you apply

    *Provided through independent charitable patient assistance programs; program eligibility is based on the charity's criteria. Amgen has no control over independent, third-party programs and provides referrals as a courtesy only.

    Call us at 1-888-4ENBREL (1-888-436-2735).

    Are you without insurance?

    Amgen Safety Net Foundation is a nonprofit patient assistance program that provides access to ENBREL at no cost for qualifying patients who are uninsured or have an insurance plan that excludes ENBREL

    Learn More

    Prescription Enbrel® (etanercept) is taken (given) by injection.

    IMPORTANT SAFETY INFORMATION

    What is the most important information I should know about ENBREL?

    ENBREL is a medicine that affects your immune system. ENBREL can lower the ability of your immune system to fight infections. Serious infections have happened in patients taking ENBREL. These infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some patients have died from these infections. Your healthcare provider should test you for TB before you take ENBREL and monitor you closely for TB before, during, and after ENBREL treatment, even if you have tested negative for TB.

    There have been some cases of unusual cancers, some resulting in death, reported in children and teenage patients who started using tumor necrosis factor (TNF) blockers before 18 years of age. Also, for children, teenagers, and adults taking TNF blockers, including ENBREL, the chances of getting lymphoma or other cancers may increase. Patients with RA may be more likely to get lymphoma.

    Before starting ENBREL, tell your healthcare provider if you:

    • Have any existing medical conditions
    • Are taking any medicines, including herbals
    • Think you have, are being treated for, have signs of, or are prone to infection. You should not start taking ENBREL if you have any kind of infection, unless your healthcare provider says it is okay
    • Have any open cuts or sores
    • Have diabetes, HIV, or a weak immune system
    • Have TB or have been in close contact with someone who has had TB
    • Were born in, lived in, or traveled to countries where there is more risk for getting TB. Ask your healthcare provider if you are not sure
    • Live, have lived in, or traveled to certain parts of the country (such as, the Ohio and Mississippi River valleys, or the Southwest) where there is a greater risk for certain kinds of fungal infections, such as histoplasmosis. These infections may develop or become more severe if you take ENBREL. If you don’t know if these infections are common in the areas you’ve been to, ask your healthcare provider
    • Have or have had hepatitis B
    • Have or have had heart failure
    • Develop symptoms such as persistent fever, bruising, bleeding, or paleness while taking ENBREL
    • Use the medicine Kineret (anakinra), Orencia (abatacept), or Cytoxan (cyclophosphamide)
    • Are taking anti-diabetic medicines
    • Have, have had, or develop a serious nervous disorder, seizures, any numbness or tingling, or a disease that affects your nervous system such as multiple sclerosis or Guillain-Barré syndrome
    • Are scheduled to have surgery
    • Have recently received or are scheduled for any vaccines. All vaccines should be brought up-to-date before starting ENBREL. Patients taking ENBREL should not receive live vaccines.
    • Are allergic to rubber or latex
    • Are pregnant, planning to become pregnant, or breastfeeding
    • Have been around someone with chicken pox

    What are the possible side effects of ENBREL?

    ENBREL can cause serious side effects including: New infections or worsening of infections you already have; hepatitis B can become active if you already have had it; nervous system problems, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes; blood problems (some fatal); new or worsening heart failure; new or worsening psoriasis; allergic reactions; autoimmune reactions, including a lupus-like syndrome and autoimmune hepatitis.

    Common side effects include: Injection site reactions and upper respiratory infections (sinus infections).

    In general, side effects in children were similar in frequency and type as those seen in adult patients. The types of infections reported were generally mild and similar to those usually seen in children.

    These are not all the side effects with ENBREL. Tell your healthcare provider about any side effect that bothers you or does not go away.

    If you have any questions about this information, be sure to discuss them with your healthcare provider. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

    Please see Prescribing Information and Medication Guide.

    INDICATIONS

    Moderate to Severe Rheumatoid Arthritis (RA)

    ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.

    Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)

    ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.

    Psoriatic Arthritis

    ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used with or without methotrexate.

    Ankylosing Spondylitis (AS)

    ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

    Moderate to Severe Plaque Psoriasis

    ENBREL is indicated for chronic moderate to severe plaque psoriasis (PsO) in children 4 years and older and adults who may benefit from taking injections or pills (systemic therapy) or phototherapy (ultraviolet light).

    • See More
    • Close

    IMPORTANT SAFETY INFORMATION

    What is the most important information I should know about ENBREL?

    ENBREL is a medicine that affects your immune system. ENBREL can lower the ability of your immune system to fight infections. Serious infections have happened in patients taking ENBREL. These infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some patients have died from these infections. Your healthcare provider should test you for TB before you take ENBREL and monitor you closely for TB before, during, and after ENBREL treatment, even if you have tested negative for TB.

    There have been some cases of unusual cancers, some resulting in death, reported in children and teenage patients who started using tumor necrosis factor (TNF) blockers before 18 years of age. Also, for children, teenagers, and adults taking TNF blockers, including ENBREL, the chances of getting lymphoma or other cancers may increase. Patients with RA may be more likely to get lymphoma.

    Before starting ENBREL, tell your healthcare provider if you:

    • Have any existing medical conditions
    • Are taking any medicines, including herbals
    • Think you have, are being treated for, have signs of, or are prone to infection. You should not start taking ENBREL if you have any kind of infection, unless your healthcare provider says it is okay
    • Have any open cuts or sores
    • Have diabetes, HIV, or a weak immune system
    • Have TB or have been in close contact with someone who has had TB
    • Were born in, lived in, or traveled to countries where there is more risk for getting TB. Ask your healthcare provider if you are not sure
    • Live, have lived in, or traveled to certain parts of the country (such as, the Ohio and Mississippi River valleys, or the Southwest) where there is a greater risk for certain kinds of fungal infections, such as histoplasmosis. These infections may develop or become more severe if you take ENBREL. If you don’t know if these infections are common in the areas you’ve been to, ask your healthcare provider
    • Have or have had hepatitis B
    • Have or have had heart failure
    • Develop symptoms such as persistent fever, bruising, bleeding, or paleness while taking ENBREL
    • Use the medicine Kineret (anakinra), Orencia (abatacept), or Cytoxan (cyclophosphamide)
    • Are taking anti-diabetic medicines
    • Have, have had, or develop a serious nervous disorder, seizures, any numbness or tingling, or a disease that affects your nervous system such as multiple sclerosis or Guillain-Barré syndrome
    • Are scheduled to have surgery
    • Have recently received or are scheduled for any vaccines. All vaccines should be brought up-to-date before starting ENBREL. Patients taking ENBREL should not receive live vaccines.
    • Are allergic to rubber or latex
    • Are pregnant, planning to become pregnant, or breastfeeding
    • Have been around someone with chicken pox

    What are the possible side effects of ENBREL?

    ENBREL can cause serious side effects including: New infections or worsening of infections you already have; hepatitis B can become active if you already have had it; nervous system problems, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes; blood problems (some fatal); new or worsening heart failure; new or worsening psoriasis; allergic reactions; autoimmune reactions, including a lupus-like syndrome and autoimmune hepatitis.

    Common side effects include: Injection site reactions and upper respiratory infections (sinus infections).

    In general, side effects in children were similar in frequency and type as those seen in adult patients. The types of infections reported were generally mild and similar to those usually seen in children.

    These are not all the side effects with ENBREL. Tell your healthcare provider about any side effect that bothers you or does not go away.

    If you have any questions about this information, be sure to discuss them with your healthcare provider. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

    Please see Prescribing Information and Medication Guide.

    INDICATIONS

    Moderate to Severe Rheumatoid Arthritis (RA)

    ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.

    Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)

    ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.

    Psoriatic Arthritis

    ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used with or without methotrexate.

    Ankylosing Spondylitis (AS)

    ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

    Moderate to Severe Plaque Psoriasis

    ENBREL is indicated for chronic moderate to severe plaque psoriasis (PsO) in children 4 years and older and adults who may benefit from taking injections or pills (systemic therapy) or phototherapy (ultraviolet light).

    Prescription Enbrel® (etanercept) is taken (given) by injection.

    IMPORTANT SAFETY INFORMATION

    What is the most important information I should know about ENBREL?

    ENBREL is a medicine that affects your immune system. ENBREL can lower the ability of your immune system to fight infections. Serious infections have happened in patients taking ENBREL. These infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some patients have died from these infections. Your healthcare provider should test you for TB before you take ENBREL and monitor you closely for TB before, during, and after ENBREL treatment, even if you have tested negative for TB.

    There have been some cases of unusual cancers, some resulting in death, reported in children and teenage patients who started using tumor necrosis factor (TNF) blockers before 18 years of age. Also, for children, teenagers, and adults taking TNF blockers, including ENBREL, the chances of getting lymphoma or other cancers may increase. Patients with RA may be more likely to get lymphoma.

    Before starting ENBREL, tell your healthcare provider if you:

    • Have any existing medical conditions
    • Are taking any medicines, including herbals
    • Think you have, are being treated for, have signs of, or are prone to infection. You should not start taking ENBREL if you have any kind of infection, unless your healthcare provider says it is okay
    • Have any open cuts or sores
    • Have diabetes, HIV, or a weak immune system
    • Have TB or have been in close contact with someone who has had TB
    • Were born in, lived in, or traveled to countries where there is more risk for getting TB. Ask your healthcare provider if you are not sure
    • Live, have lived in, or traveled to certain parts of the country (such as, the Ohio and Mississippi River valleys, or the Southwest) where there is a greater risk for certain kinds of fungal infections, such as histoplasmosis. These infections may develop or become more severe if you take ENBREL. If you don’t know if these infections are common in the areas you’ve been to, ask your healthcare provider
    • Have or have had hepatitis B
    • Have or have had heart failure
    • Develop symptoms such as persistent fever, bruising, bleeding, or paleness while taking ENBREL
    • Use the medicine Kineret (anakinra), Orencia (abatacept), or Cytoxan (cyclophosphamide)
    • Are taking anti-diabetic medicines
    • Have, have had, or develop a serious nervous disorder, seizures, any numbness or tingling, or a disease that affects your nervous system such as multiple sclerosis or Guillain-Barré syndrome
    • Are scheduled to have surgery
    • Have recently received or are scheduled for any vaccines. All vaccines should be brought up-to-date before starting ENBREL. Patients taking ENBREL should not receive live vaccines.
    • Are allergic to rubber or latex
    • Are pregnant, planning to become pregnant, or breastfeeding
    • Have been around someone with chicken pox

    What are the possible side effects of ENBREL?

    ENBREL can cause serious side effects including: New infections or worsening of infections you already have; hepatitis B can become active if you already have had it; nervous system problems, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes; blood problems (some fatal); new or worsening heart failure; new or worsening psoriasis; allergic reactions; autoimmune reactions, including a lupus-like syndrome and autoimmune hepatitis.

    Common side effects include: Injection site reactions and upper respiratory infections (sinus infections).

    In general, side effects in children were similar in frequency and type as those seen in adult patients. The types of infections reported were generally mild and similar to those usually seen in children.

    These are not all the side effects with ENBREL. Tell your healthcare provider about any side effect that bothers you or does not go away.

    If you have any questions about this information, be sure to discuss them with your healthcare provider. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

    Please see Prescribing Information and Medication Guide.

    INDICATIONS

    Moderate to Severe Rheumatoid Arthritis (RA)

    ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.

    Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)

    ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.

    Psoriatic Arthritis

    ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used with or without methotrexate.

    Ankylosing Spondylitis (AS)

    ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

    Moderate to Severe Plaque Psoriasis

    ENBREL is indicated for chronic moderate to severe plaque psoriasis (PsO) in children 4 years and older and adults who may benefit from taking injections or pills (systemic therapy) or phototherapy (ultraviolet light).